SCHEMBL24798475

SCHEMBL24798475

Cc1nc2cc(C=O)ccn2c1-c1ccccc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ AKT1 P31749 10/20 0.41
▸ AKT2 P31751 10/20 0.41
▸ COMT P21964 1/20 0.38
▸ ALDH1A1 P00352 3/20 0.38
▸ POLB P06746 1/20 0.38
▸ CGAS Q8N884 1/20 0.37
▸ HDAC1 Q13547 4/20 0.37
▸ KDM4E B2RXH2 2/20 0.37
▸ HPGD P15428 2/20 0.37
▸ SMN1; SMN2 Q16637 2/20 0.37
▸ BRD4 O60885 1/20 0.37
▸ MEN1 O00255 1/20 0.37
▸ LMNA P02545 1/20 0.37
▸ GAA P10253 1/20 0.37
▸ MAPT P10636 1/20 0.37
▸ ALOX12 P18054 1/20 0.37
▸ MAPK1 P28482 1/20 0.37
▸ HTT P42858 1/20 0.37
▸ KMT2A Q03164 1/20 0.37
▸ NPSR1 Q6W5P4 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1445427 0.78 NPC1 (0.51) AKT1AKT2ALDH1A1SMN1; SMN2MEN1
SCHEMBL9611707 0.75 ALDH1A1 (0.56) ALDH1A1POLBKDM4EHPGDGAA
SCHEMBL22782754 0.74 NPC1 (0.45) AKT1AKT2ALDH1A1CGASHDAC1
SCHEMBL24798078 0.70 CYP2A6 (0.36) ALDH1A1HDAC1KDM4EMAPT
SCHEMBL31511 0.70 AKT1 (0.60) AKT1AKT2ALDH1A1HPGDSMN1; SMN2
SCHEMBL13325914 0.70 AKT2 (0.56) AKT1AKT2HDAC1
SCHEMBL10225289 0.69 LIPG (0.46) AKT1AKT2COMTALDH1A1POLB
SCHEMBL973664 0.69 ALDH1A1 (0.38) AKT1AKT2ALDH1A1POLBKDM4E
SCHEMBL13266511 0.68 KDM4E (0.57) ALDH1A1POLBKDM4EHPGDSMN1; SMN2
SCHEMBL1429406 0.67 AKT2 (0.66) AKT1AKT2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3697785-B1 IMIDAZO-PYRIDINE COMPOUNDS AS PAD INHIBITORS Jubilant Epipad LLC (US) 2022-12-28 — — EP disclosed
Send feedback